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Abstract
Cerebral blood flow (CBF) reductions in Alzheimer’s disease (AD) patients and related mouse 
models have been recognized for decades, but the underlying mechanisms and resulting 
consequences on AD pathogenesis remain poorly understood. In APP/PS1 and 5xFAD mice we 
found that an increased number of cortical capillaries had stalled blood flow as compared to 
wildtype animals, largely due to neutrophils that adhered in capillary segments and blocked blood 
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flow. Administration of antibodies against the neutrophil marker Ly6G reduced the number of 
stalled capillaries, leading to an immediate increase in CBF and to rapidly improved performance 
in spatial and working memory tasks. This study identified a novel cellular mechanism that 
explains the majority of the CBF reduction seen in two mouse models of AD and demonstrated 
that improving CBF rapidly improved short-term memory function. Restoring cerebral perfusion 
by preventing neutrophil adhesion may provide a novel strategy for improving cognition in AD 
patients.
Introduction
Alzheimer’s disease (AD) is the most common form of dementia in the elderly, worldwide. 
AD is characterized by a rapid and progressive cognitive decline accompanied by several 
pathological features, such as the accumulation of amyloid-beta (Aβ) plaques in brain tissue 
and along blood vessels as cerebral amyloid angiopathy, the hyperphosphorylation of tau 
proteins and formation of neurofibrillary tangles in neurons, increased density and activation 
of inflammatory cells, and ultimately the death of neurons and other brain cells1.
Vascular dysfunction is implicated in the pathogenesis of AD. Many of the primary risk 
factors for AD are associated with compromised vascular structure and function, such as 
obesity, diabetes, atherosclerosis, and hypertension2. Brain blood flow is also severely 
compromised in AD, with both patients with AD3-5 and mouse models of AD6-8, which 
express mutated genes that encode for amyloid precursor protein (APP), exhibiting cortical 
cerebral blood flow (cCBF) reductions of ~25% early in disease development. Several 
mechanisms for this hypoperfusion had been proposed including constriction of brain 
arterioles9, loss of vascular density10, and changes in neural activity patterns and/or in 
neurovascular coupling11,12, but a full understanding of the underlying mechanisms for CBF 
reduction in AD has not emerged.
These large blood flow decreases could contribute to the cognitive symptoms of AD and 
drive disease progression. Cognitive functions, such as attention, were immediately impaired 
by CBF reductions of ~20% in healthy humans13. When CBF was chronically reduced by 
~35% in wildtype (wt) mice, spatial memory deficits were observed, accompanied by 
pathological changes in the brain including increased inflammation14. In addition, impairing 
blood flow in AD mouse models led to an increase in Aβ deposition, suggesting that blood 
flow deficits can worsen Aβ pathology14,15. These data suggest that the decreased CBF in 
AD likely contributes to both the cognitive dysfunction and to disease progression.
Because CBF reductions have been a recognized and important aspect of AD, yet have not 
been well explained, we sought to uncover the cellular basis for these flow reductions in the 
APP/PS1 and 5xFAD mouse models of APP overexpression.
Results
To investigate cortical hypoperfusion in AD, we used in vivo two-photon excited 
fluorescence (2PEF) microscopy to image the cortical vasculature in APP/PS1 mice16 (Fig. 
1a) and looked for occluded vessels (Fig. 1b). We observed no obstructions in arterioles or 
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venules, but about 1.8% of capillaries in APP/PS1 mice had stalled blood flow, while age- 
and sex-matched, wt littermates had 0.4% of capillaries not flowing (Fig. 1c, video S1 and 
S2). The number of stalled capillaries was elevated by 12 weeks of age in APP/PS1 mice, 
and remained elevated throughout disease progression (Fig. 1d). Flowing and stalled 
capillaries (Fig. 1e) had about the same distance distribution relative to the nearest 
penetrating arteriole (Fig. 1f) or ascending venule (Fig. 1g). The incidence of capillary 
stalling did not increase with Aβ plaque density (Supplementary Fig. 1a), and was the same 
in awake and anesthetized animals (video S3 and S4; Supplementary Fig. 1b). Capillary 
stalling was similarly elevated in 5–6 month old 5xFAD (Supplementary Fig. 2a) and 10–13 
month old TgCRND8 mice17 (Supplementary Fig. 3), two different mouse model of APP 
overexpression.
Using labeling strategies to distinguish leukocytes, platelets, and RBCs (Fig. 2a), we found 
the majority of stalled capillary segments in APP/PS1 mice contained a leukocyte, 
sometimes with and sometimes without one or more RBCs also present in the capillary 
segment (Fig. 2b). We injected a low dose of fluorescently labeled antibodies against Ly6G, 
a neutrophil surface marker (0.1 mg/kg animal weight, intravenous), and found that the vast 
majority of capillary stalls had a labeled cell present (Fig. 2c; 26 of 30 identified capillary 
stalls across four mice were labeled). Stalled capillaries had a modestly smaller average 
diameter than flowing capillaries (Fig. 2d), but no difference in the density of nearby Aβ 
deposits (Fig. 2e). Most plugged capillaries were transiently stalled with a half-life of less 
than 5 min, while one-third remained stalled for 15 min and 10% began flowing and then re-
stalled within 15 min (Fig. 2f; Supplementary Fig. 4). We also observed that some capillary 
segments alternated between flowing and stalled in repeated imaging sessions over weeks 
(Fig. 2g). The same capillaries were stalled across multiple imaging sessions about ten times 
as frequently as predicted by a statistical model that assumed each capillary had an equal 
probability of being stalled at any time point (Fig. 2h). Taken together, these data suggest 
that the capillary stalls were caused by leukocytes (likely neutrophils based on the specificity 
of Ly6G expression18) plugging a distinct subset of capillary segments.
We serendipitously found that administration of a much higher dose of fluorescently-labeled 
antibodies against Ly6G (α-Ly6G; 4 mg/kg animal weight, intraperitoneal) reduced the 
number of stalled capillaries within 10 min (Fig. 3a and Supplementary Fig. 5). Isotype 
control (Iso-Ctr) antibodies did not impact capillary stalling. Using flow cytometry 
(Supplementary Fig. 6a) we found that α-Ly6G administration led to no change in the 
number of circulating neutrophils at three hours (Supplementary Fig. 6b), but did lead to 
~50% depletion by six hours (Supplementary Fig. 6c) and near complete depletion by 24 
hours (Supplementary Fig. 6d). Median volumetric blood flow in penetrating arterioles, 
measured using 2PEF (Fig. 3b) and characterizing blood flow into the cortex, increased by 
26% in young (3–4 months) and 32% in aged (11–14 months) APP/PS1 mice one hour after 
α-Ly6G administration (Fig. 3c). This increase in penetrating arteriole blood flow was due 
to an increase in RBC speed and not an increase in vessel diameter (Supplementary Fig. 7a 
and b). Penetrating arterioles with lower baseline flow tended to show larger flow increases 
(Supplementary Fig. 7c). Iso-Ctr antibodies did not change penetrating arteriole blood flow 
in APP/PS1 mice, nor did α-Ly6G in wt animals (Fig. 3c). We also used arterial spin labeled 
MRI (ASL-MRI) to measure cCBF in 7–9-month old animals (Fig 3d). At baseline, average 
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cCBF in APP/PS1 mice was 17% lower than in wt animals (Fig. 3e). cCBF increased by 
13% in APP/PS1 mice at ~5 hr after α-Ly6G administration, recovering about two-thirds of 
the deficit relative to wt animals, but was unchanged in APP/PS1 mice given Iso-Ctr 
antibodies or wt mice given α-Ly6G (Fig. 3e). To establish the timeline for these CBF 
increases, we used multi-exposure laser speckle contrast imaging to quantify changes in 
CBF over the first three hours after antibody administration in APP/PS1 mice. CBF 
increased within the first 10 min after α-Ly6G administration and remained elevated over 
the three hours (Supplementary Fig. 8). Isotype control antibodies did not lead to significant 
changes in CBF (Supplementary Fig. 8). In 5–6 month old 5xFAD mice we also found that 
α-Ly6G administration led to a reduction in the number of stalled capillaries 
(Supplementary Fig. 2a) and an increase in blood flow in cortical penetrating arterioles 
(Supplementary Fig. 2b-d) within an hour. Thus, administration of α-Ly6G led to a rapid 
reduction in the number of capillary stalls that was accompanied by a rapid increase in cCBF 
in APP/PS1 and 5xFAD mice. In contrast, when antibodies against LFA-1 were administered 
to 11–13 month old APP/PS1 mice, we did not observe a rapid decrease in the number of 
stalled capillaries. Instead, we found that capillary stalls were reduced and penetrating 
arteriole blood flow was increased at one day after antibody injection, when circulating 
leukocytes had been depleted (Supplementary Fig. 9). Across all antibody and control 
treatments in APP/PS1 mice, penetrating arteriole flows increased (decreased) when the 
number of stalled capillaries decreased (increased) (Supplementary Fig. 9g).
We next tested whether α-Ly6G administration improves cognitive function in APP/PS1 
(Fig. 4a) and 5xFAD mice. In the object replacement (OR) test of spatial short-term memory 
(Fig. 4b), a single dose of α-Ly6G in ~11-month old APP/PS1 mice improved performance 
to the level of wt animals at 3 and 24 hours after administration (Fig. 4c; Supplementary Fig. 
10a). APP/PS1 mice treated with Iso-Ctr antibodies showed no change, nor did wt animals 
with α-Ly6G (Fig. 4c). In ~6 month old 5xFAD mice, a single dose of α-Ly6G improved 
animal performance in the OR task at 24 hours, with this trend evident at 3 hours 
(Supplementary Fig. 11a and b). Similarly, α-Ly6G improved performance of APP/PS1 and 
5xFAD mice in the Y-maze test of working memory (Fig. 4d, Supplementary Fig. 10b, and 
Supplementary Fig. 11c and d). We detected no improvement in sensory-motor function 
(balance beam walk, Supplementary Fig. 12a-d) nor in depression- and anxiety-like behavior 
(forced swim, Supplementary Fig. 12e) in APP/PS1 mice with α-Ly6G. To exclude an 
antibody specific effect we repeated the OR and Y-maze behavioral tests in another cohort of 
APP/PS1 mice before and after administration of α-LFA-1 antibodies and found improved 
performance on both tests at 24 hours (Supplementary Fig. 13a-d).
We continued to treat the APP/PS1 mice that received α-Ly6G with additional doses of α-
Ly6G every three days for a month, resulting in depletion of neutrophils (Supplementary 
Fig. 6e). After this regimen, APP/PS1 mice exhibited short-term memory performance that 
matched wt animals in OR (Fig. 4c), Y-maze (Fig. 4d), and novel object recognition (NOR) 
(Fig. 4e; Supplementary Fig. 10c and d). We saw no improvement in sensory-motor function 
(Supplementary Fig. 12a-d) nor in depression- and anxiety-like behavior (Supplementary 
Fig. 12e).
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Because one of the clearance pathways for Aβ is through the vasculature19 we assessed 
whether improving cCBF with α-Ly6G decreases the concentration of Aβ monomers and 
aggregates. Using enzyme-linked immunosorbent assays (ELISAs) of brain extracts from the 
animals that received one month of antibody treatment, we found that α-Ly6G reduced the 
concentration of Aβ1–40 compared to Iso-Ctr antibodies (Fig. 5a), while the concentration of 
Aβ1–42 (Fig. 5b) and aggregates of Aβ (Supplementary Fig. 14d) remained unchanged. We 
saw no difference in the number and density of Aβ plaques between α-Ly6G and Iso-Ctr 
treated animals (Supplementary Fig. 14a – c).
Finally, we addressed the question of how only ~2% of capillaries being stalled could 
explain the dramatic blood flow changes we observed after α-Ly6G administration. Because 
each occluded capillary decreases blood flow in up- and down-stream vessels20, a small 
number of stalled capillaries could have an outsized impact on CBF. To estimate the 
magnitude of this impact and to compare how the topology of the cortical capillary network 
influences the result, we simulated blood flow in vascular networks from a 1 mm3 volume of 
mouse parietal cortex (Fig. 6a)21, a 6 mm3 volume of human cortex (Fig. 6b)22, and a 
synthetic periodic network of order three (Supplementary Fig. 15a) using a non-linear model 
of microvascular blood flow23 (see Supplementary Methods and Supplementary Note). 
cCBF decreased linearly with an increasing fraction of stalled capillaries, without any 
threshold effect, across all three networks (Fig. 6c), demonstrating that, on average, each 
single capillary occlusion has a similar, and cumulative, impact on blood flow. Moreover, the 
slope of the CBF decrease with increasing capillary stalls was almost identical between the 
mouse, human, and artificial networks, suggesting that capillary stalling may impact CBF 
similarly across three-dimensional capillary networks with three vessels connected at each 
node. Quantitatively, these simulations predicted a ~5% (10%) deficit in cCBF due to 2% 
(4%) of capillaries stalled (relative to the case with no capillary stalls), which is smaller than 
the increase in CBF we observed with 2PEF and ASL-MRI measurements after α-Ly6G 
administration.
Discussion
In this study, we aimed to uncover the cellular mechanisms contributing to reduced cCBF in 
AD and to determine the impact of this reduced cCBF on cognitive function. Brain blood 
flow reductions occur in the vast majority of dementia patients, including those with AD. 
These blood flow reductions are one of the earliest features of AD progression3,24. Mouse 
models that express mutant APP also show comparable reductions in CBF6-8.
Previous studies have implicated a variety of potential mechanisms in the CBF reductions 
seen in AD. Amyloid beta monomers were found to drive vasoconstriction in brain arterioles 
that could contribute to a reduction in resting CBF9. In AD, there is a faster loss of vascular 
density with age, which could reduce cerebral perfusion10. In addition to decreases in 
baseline perfusion, the regulation of blood flow in the brain is compromised in AD. Vessel 
diameter changes in response to CO2 inhalation, blood pressure changes, and changes in 
local neural activity are all attenuated in AD patients and mouse models of APP 
overexpression25. This loss of dynamic regulation of cerebral blood flow could also 
contribute to cognitive impacts. Indeed, recent work showed that restoring cerebrovascular 
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function, by angiotensin receptor inhibition or by reducing vascular oxidative stress, led to 
improved cognitive function12,26,27.
Our data reveal that neutrophil plugging of individual capillary segments is a previously 
unrecognized mechanism that significantly contributes to the CBF reduction in AD mouse 
models. The rapid resolution of the capillary stalls after α-Ly6G treatment suggests the stalls 
are caused by receptor-mediated interactions of neutrophils with the capillary 
endothelium28, likely due to increased endothelial inflammation. Ly6G has long been 
appreciated as a neutrophil-specific marker29. Consistent with our findings, it has recently 
been shown that inhibiting Ly6G signaling leads to decreased migration of neutrophils 
toward sites of inflammation by modulating β2-integrin-dependent adhesion28. There may, 
however, be other mechanisms that contribute to the reduction in capillary stalling after α-
Ly6G treatment. We observed that stalled capillaries had a modestly smaller diameter, on 
average, than flowing capillaries and a receptor-mediated increase in the mechanical 
stiffness of neutrophils that was blocked by α-Ly6G might allow for easier deformation and 
passage of neutrophils through the narrowed capillaries30. While some mouse models of AD 
have shown severe alterations in the topology of the cortical vascular network, recent work 
has shown that there are relatively minor differences in the capillary density and tortuosity 
between APP/PS1 and wt mice, suggesting differences in vascular structure likely do not 
underlie the increase in capillary stalling in APP/PS1 mice31,32.
Capillary obstructions due to tissue inflammation have been observed in a variety of organ 
systems (typically at higher incidence than observed here) and have been shown to 
contribute to the pathology and disease development33-39. Inflammation is a persistent and 
well-recognized feature of AD and previous work has demonstrated an increase in 
inflammatory adhesion receptors on endothelial cells40–42, which likely underlies the 
capillary stalling we observed. A significant contributor to this inflammation is increased 
reactive oxygen species (ROS) induced by brain exposure to Aβ oligomeric aggregates26. 
These ROS cause a loss of cerebrovascular flow regulation and likely drive the expression of 
leucocyte-binding receptors on the endothelial cell surface, such as ICAM1 and VCAM1. 
Our observation that some capillary segments were more likely to stall suggests that the 
underlying vascular inflammation may not be uniform.
While here our focus has been on increased leukocyte adherence causing a subset of 
capillaries to be transiently stalled due to a firmly adhered leukocyte, this increased 
leukocyte adherence likely also contributes to slowed, but not stalled, flow in other capillary 
segments when a leukocyte is present. Our experimental approach does not enable us to 
readily detect such slowed vessels. Our simulations included only the impact of completely 
stalled vessels, which may have contributed to the model’s underestimation of the increase 
in CBF after α-Ly6G administration. However, the simulations predicted a similar 
sensitivity of brain blood flow to capillary stalling in humans and mice, suggesting that, if 
capillary stalling occurs in AD patients, significant blood flow improvements could be 
achieved.
We observed spatial and working memory improvements within 24 hours after treatment 
with antibodies against Ly6G and/or LFA-1 in multiple mouse models of AD. The temporal 
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correlation between reduced capillary stalling/blood flow increase and the improvement in 
cognitive function suggests that a mismatch between neuronal energy metabolism and 
delivery of energy substrates through blood flow contributes to the cognitive deficit in these 
AD mouse models.
We also observed improved cognitive function after one month of treatment with α-Ly6G, 
which depletes neutrophils, in APP/PS1 mice, measured during the antibody therapy. 
Because of the persistent depletion of neutrophils during this treatment, we expect that 
capillary stalling was reduced and brain blood flow increased throughout the month, 
including during cognitive testing, which likely contributed to the improved cognitive 
performance. In previous work by Zenaro, et al., treatment with antibodies that deplete 
neutrophils (α-GR-1, α-LFA-1, and α-Ly6G) for one month in multiple AD mouse models 
(3xTg and 5xFAD), remarkably, led to a persistent improvement in cognitive performance, 
measured a month after the end of antibody therapy42. This persistent improvement in 
cognitive function was attributed to a decrease in the number of neutrophils present in the 
brain parenchyma due to their antibody-mediated depletion and a resulting decrease in 
neuroinflammation, and it is likely this mechanism contributed to the improvement in 
cognitive performance we observed after one month of antibody therapy. Taken together, 
these studies show that neutrophil interactions in the vasculature and parenchyma of the 
brain play a crucial role in the impaired cognitive function observed in multiple mouse 
models of amyloid-beta overexpression.
Without a firm understanding of the underlying mechanisms that caused reduced CBF in 
AD, no medical approach to increasing brain blood flow has been developed or tested in 
humans. In a limited series of experiments in severe AD patients, a piece of omentum, which 
is known to secrete angiogenic factors and encourage new vessel growth, was surgically 
placed on the surface of the brain. In the patients that showed an increased CBF as a result, 
there were signs of improved cognitive function5,43 Accordingly, improving CBF by 
interfering with neutrophil adhesion could be a promising therapeutic approach for AD.
Methods
Animals and surgical preparation
All animal procedures were approved by the Cornell Institutional Animal Care and Use 
Committee (protocol numbers: 2009–0043 and 2015–0029) and were performed under the 
guidance of the Cornell Center for Animal Resources and Education. We used adult 
transgenic mice as mouse models of AD, including the APP/PS1 line (B6.Cg-Tg (APPswe, 
PSEN1dE9) 85Dbo/J; MMRRC_034832-JAX, The Jackson Laboratory)45 and the 5xFAD 
line (B6SJL-Tg(APPSwFlLon,PSEN1 *M146L*L286V)6799Vas/Mmjax; MMRRC Stock 
No: 34840-JAX, The Jackson Laboratory)46. Littermate wild-type mice (C57BL/6) were 
used as controls. Animals were of both sexes and ranged in age from 12 to 100 weeks.
For cranial window implantation, mice were anesthetized under 3% isoflurane on a custom-
built stereotactic surgery frame and then maintained on ~1.5% isoflurane in 100% oxygen. 
Once unresponsive to a toe pinch, mice were given 0.05 mg per 100 g of mouse weight of 
glycopyrrolate (Baxter Inc.) or 0.005 mg/100 g of atropine (54925–063-10, Med-Pharmex 
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Inc.) to prevent lung secretions, 0.025 mg/100 g of dexamethasone (07–808-8194, Phoenix 
Pharm Inc.) to reduce post-surgical inflammation, and 0.5 mg/100 g of ketoprofen (Zoetis 
Inc.) to reduce post-surgical inflammation and provide post-surgical analgesia. 
Glycopyrrolate and ketoprofen were injected intramuscularly, while atropine and 
dexamethasone were injected subcutaneously. Bupivacaine (0.1 ml, 0.125%) (Hospira Inc.) 
was subcutaneously administered at the incision site to provide a local nerve block. Animals 
were provided 1 ml per 100 g of mouse weight of 5% (w/v) glucose in normal saline 
subcutaneously every hour during the procedure. We used a thermometer and feedback-
controlled heating blanket (40–90-8D DC, FHC) to maintain body temperature at 37 °C. The 
head was shaved and washed 3 times with alternating 70% (v/v) ethanol and iodine solutions 
(AgriLabs). A 6-mm diameter craniotomy was performed over the cerebral cortex using a 
high-speed drill (HP4–917-21, Fordom) using bits with diameters of 1.4, 0.9, 0.7, and 0.5 
mm (Fine Science Tools) for different steps in the craniotomy procedure. The craniotomy 
was then covered with a sterile 8-mm diameter glass coverslip (11986309, Thermo 
Scientific), glued onto the remaining skull with cyanoacrylate adhesive (Loctite) and dental 
cement (Co-Oral-Ite Dental). All procedures were done using sterile technique.
Once the craniotomy was completed, mice were returned to their cages and given injections 
of 0.025 mg/100 g of dexamethasone and 0.5 mg/100 g of ketoprofen subcutaneously 1 and 
2 days after surgery, and all cages were placed over a heating pad during this period. 
Animals were given at least two weeks to recover from cranial window implantation before 
experimentation to minimize inflammation from the surgical procedure. Animals were 
excluded from further study if the clarity of the imaging window was insufficient for 2PEF 
imaging.
In vivo two-photon microscopy
During imaging sessions, mice were anesthetized with 3% isoflurane, placed on a custom 
stereotactic frame, and were given glycopyrrolate or atropine and glucose as described 
above. During imaging, anesthesia was maintained with ~1.5% isoflurane in 100% oxygen, 
with small adjustments to the isoflurane made to maintain the respiratory rate at ~1 Hz. The 
mouse was kept at 37 °C with a feedback-controlled heating pad.
To fluorescently label the microvasculature, Texas Red dextran (40 μl, 2.5%, MW = 70,000 
kDA, Thermo Fisher Scientific) in saline was injected retro-orbitally immediately prior to 
imaging. In some animals, amyloid beta (Aβ) deposits were labeled using methoxy-X0447. 
In early experiments using methoxy-X04 obtained directly from Prof. Klunk at the 
University of Pittsburgh, we retro-orbitally injected 40 µL of 1 mg/ml methoxy-X04 in 0.9% 
saline (adjusted to pH 12 with 0.1 N NaOH) immediately prior to imaging. In later 
experiments using methoxy-X04 available commercially from Tocris, we intraperitoneally 
injected methoxy-X04 (dissolved in DMSO at 100 mM) one day prior to imaging at a dose 
of 1 mg/100 g. We observed no obvious differences in the amyloid labeling between these 
two administration approaches. In some animals, leukocytes and blood platelets were 
labeled with a retro-orbital injection of Rhodamine 6G (0.1 ml, 1 mg/ml in 0.9% saline, 
Acros Organics, Pure)38. Leukocytes were distinguished from blood platelets with a retro-
orbital injection of Hoechst 33342 (50 μl, 4.8 mg/ml in 0.9% saline, Thermo Fisher 
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Scientific). Texas Red (and methoxy-X04, when given retro-orbitally) were dosed in a single 
syringe, while Rhodamine 6G and Hoechst were dosed together in a second syringe.
Three-dimensional images of the cortical vasculature and measurement of red blood cell 
flow speeds in specific vessels were obtained via a custom-built two-photon excited 
fluorescence (2PEF) microscope. Imaging was done using 830-nm, 75-fs pulses from a 
Ti:Sapphire laser oscillator (MIRA HP pumped by a Verdi-V18 or Vision S, Coherent) and 
900-nm, 75-fs pulses from a second Ti:Sapphire laser oscillator (Vision S, Coherent). Lasers 
were scanned by galvonometric scanners (1 frame/s) and focused into the sample using a 
20× water-immersion objective lens for high-resolution imaging (numerical aperture (NA) = 
1.0, Carl Zeiss Microscopy; or NA = 0.95, Olympus), or a 4× objective for mapping of the 
cortical surface vasculature (NA = 0.28, Olympus). The emitted fluorescence was detected 
on either a two-channel detection system or, for later data sets, on an upgraded four-channel 
detection system. On the two-channel system, the fluorescence was split by a 600-nm long 
pass dichroic and two successive image stacks were acquired first with 645/45 nm (center 
wavelength/bandwidth) and 575/25 nm bandpass filters to image Texas Red and Rhodamine 
6G, respectively, and then with 645/65 nm and 460/50 nm filters to image Texas Red and 
both methoxy-X04 and Hoescht (on the same channel), all under 830-nm excitation. On the 
four-channel system, a secondary long-pass dichroic at 520 nm was followed by tertiary 
long-pass dichroics at 458 nm and one at either 562 or 605 nm. Emission was detected on 
four photomultiplier tubes through the following emission filters: 417/60 nm for Hoechst, 
494/41 nm for methoxy-X04, 550/49 nm for Rhodamine 6G, and 641/75 nm for Texas Red. 
Laser excitation was 830 nm except when trying to image deep cortical tissue in animals 
where only Texas Red was present in which case 900-nm excitation was used. Laser 
scanning and data acquisition was controlled by ScanImage software48. To visualize the 
cortical vasculature, stacks of images spaced by 1 μm axially were taken to a cortical depth 
of 300–500 μm.
For imaging of neutrophils labeled with anti-Ly6G antibodies labeled with Alexa488, 
imaging was performed on a custom-built 2PEF microscope at the Wellman Center for 
Photomedicine. In these animals, neutrophils were labeled with a tail vein injection of anti-
Ly6G-Alexa 488 (0.1 mg/kg animal weight, 127626-Biolegend) at the same time as the 
labeling of blood plasma with Texas Red dextran. Imaging was done using 750-nm, 80-fs 
pulses from a Ti:Sapphire laser oscillator (Spectra-Physics Mai Tai). The laser beam was 
scanned by polygon scanners (30 frames/s) and focused into the sample using a 40x water-
immersion objective lens for high-resolution imaging (NA = 0.80, Olympus), or a 10x 
objective for mapping of the cortical surface vasculature (NA = 0.30, Olympus). The emitted 
fluorescence was detected on photomultiplier tubes through the following emission filters: 
525/50 nm for Alexa-488 and 605/50 nm for Texas Red. Laser scanning and data acquisition 
was controlled by custom built software. Stacks of images spaced by 1 μm axially were 
taken to a cortical depth of 100–200 μm.
Quantification of capillary network topology and capillary segment stalling
The 2PEF images of vascular networks were manually traced in three-dimensions to create a 
vectorized skeleton that represents the cortical vasculature using custom-written tracing 
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software. The researchers producing these tracings were blinded to the genotype of the 
animal and any treatment it had received. Volumes of these image stacks where vessels 
could not be readily identified and traced were excluded from all analysis. These regions 
were typically deep and near the edges of the imaged volume, or occasionally directly 
underneath a large surface vessel. Vessel segments were classified as surface and penetrating 
arterioles, capillaries, or ascending and surface venules. All vessels smaller than 10 µm in 
diameter were classed as capillaries. Large surface arterioles were distinguished from large 
surface venules based on morphology (arterioles were smaller diameter, had smoother walls 
and less tortuosity, and tended to branch more symmetrically and in Y-shape junctions as 
compared to venules). Other arterioles or venules were classed by tracing their connectivity 
to these readily identifiable large vessels.
Each capillary segment in these images was then manually classed as either flowing or 
stalled based on the motion of RBCs during the entire time each capillary was visible in the 
3D image stack. The Texas Red dextran labels the blood plasma, but not the blood cells, so 
RBCs and other blood cells show up as dark patches in the vessel lumen. The motion of 
these dark patches indicates flowing blood cells. Each capillary segment was visible in a 
minimum of ~5 successive frames in the 3D image stack, or for ~5 s (capillaries not oriented 
parallel to the cortical surface were observed for significantly more frames). We scored a 
capillary segment as stalled if we did not see motion of the RBCs and other cells in the 
capillary segment over this observation time. This manual scoring of capillaries as flowing 
or stalled was performed with the researcher blinded to the genotype and treatment status of 
the animal. In addition, this scoring was performed using only the image data visible on the 
Texas Red imaging channel. All animals included in our analysis had at least 800 capillary 
segments scored as flowing or stalled. Animals with fewer characterized capillaries were 
excluded.
Using the traced vascular network, the topologically shortest path from each flowing or 
stalled capillary to the nearest penetrating arteriole and ascending venule was calculated 
using Dijkstra’s algorithm49.
Distinguishing causes of capillary stalls
In some animals, once capillary stalls were identified we used the additional fluorescent 
labels to determine what was blocking blood flow in the capillary segment. Stalled capillary 
segments with a cell-shaped object labeled with both Rhodamine 6G and Hoechst present 
were scored as having a leukocyte. Stalled segments with punctate objects labeled with 
Rhodamine 6G alone were scored as having platelet aggregates. Stalled capillary segments 
with only RBCs present were classed as RBC stalls. We determined what fraction of stalled 
capillaries had only a leukocyte, a leukocyte with one or more RBCs present, only platelet 
aggregates, platelet aggregates with RBCs, and only RBCs. With this labeling scheme, we 
were unable to reliably distinguish platelet aggregates when a leukocyte was present. 
Additional experiments used a low-dose of Alexa 488 labeled anti-Ly6G antibodies to assess 
the type of leukocyte associated with capillary stalls.
We assessed if the diameter of flowing and stalled capillaries was different, on average. 
First, image stacks were linearly interpolated to have an isotropic 1 µm voxel size. To reduce 
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the salt and pepper noise in the vascular images, we filtered using a 3D 5 × 5 × 5 pixel 
Gaussian filter. We then corrected for unevenness in the image intensity by filtering the 
image (85 × 85 pixel sized mean filter) and subtracting this from the Gaussian filtered 
image. The resulting image was binarized using Otsu’s method50. Finally, objects smaller 
than 1000 voxels were eliminated, where voxels were considered part of the same connected 
object whenever they shared at least a corner. We then used this binarized image to correct 
the manual tracing of the vasculature by shifting the centerline so it was equidistant from the 
vessel boundaries (done within a 10-µm neighborhood to avoid confusion between 
neighboring capillaries). Every 5 µm along the centerline of each capillary segment, we 
estimated the vessel radius by finding the closest distance from the centerline to the vessel 
boundary. Measurements of less than 2 µm or more than 10 µm were excluded as they likely 
reflected imaging artifacts, and we averaged across all measurements for each capillary 
segment.
Administration of antibodies against Ly6G or LFA-1 to interfere with capillary stalling
We treated APP/PS1 and 5xFAD mice with intraperitoneal injections of monoclonal 
antibodies against lymphocyte antigen 6 complex, locus G (Ly6G) (α-Ly6G, clone 1A8, 4 
mg/kg, BD Biosciences) or an isotype control antibody (Rat IgG2a, κ, 4 mg/kg, BD 
Biosciences). In addition, APP/PS1 mice were treated with retroorbital or intraperitoneal 
injections of monoclonal antibodies against Lymphocyte Functional Antigen 1 (α-LFA-1; 
M17/4 clone, BD Biosciences; 4 mg/kg). The same cortical capillary bed was imaged in 
anesthetized mice immediately before and at 60–90 min after treatment. Mice were 
randomly assigned to receive treatment or isotype control antibodies and the experimenter 
was blinded to both mouse genotype and whether the antibody was the treatment or control 
during the experiment. Quantification of stalled capillaries was performed by researchers 
blinded to imaging time, animal genotype, and treatment type.
Behavior Experiments
All experiments were performed under red light in an isolated room. The position of the 
mouse’s nose was automatically traced by Viewer III software (Biobserve, Bonn, Germany). 
In addition to the automatic results obtained by Viewer III software, a blinded experimenter 
independently scored mouse behavior manually. Animals were taken into the behavior room 
one-hour prior to the experiment. Behavioral analysis was conducted at baseline and at 3 and 
24 h after injection with α-Ly6G, α-LFA-1, or isotype control antibodies (IP 4 mg/kg). The 
α-Ly6G treated APP/PS1 mice were then treated every three days for four weeks (IP 2 
mg/kg) and behavior experiments were repeated. The OR, Y-maze, balance beam walk, and 
forced swim tests were performed at all time points. The NOR task was performed only at 
baseline and the 4-week time point to avoid animals becoming accustomed to the objects. 
For experiments with APP/PS1 mice and α-Ly6G, animals were ~11 months of age at the 
start of the experiment. For experiments with APP/PS1 mice and α-LFA-1, animals were 
11–13 months of age. For experiments with 5xFAD mice and α-Ly6G, animals were 5–6 
months of age. Mice were randomly assigned to receive treatment or isotype control 
antibodies and the experimenter was blinded to both mouse genotype and whether the 
antibody was the treatment or control during the experiment.
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Object replacement test: The object replacement (OR) task evaluated spatial memory 
performance. All objects used were first validated in a separate cohort of mice to ensure that 
no intrinsic preference or aversion was observed and animals explored all objects similarly. 
Exploration time for the objects was defined as any time when there was physical contact 
with an object (whisking, sniffing, rearing on, or touching the object) or when the animal 
was oriented toward the object and the head was within 2 cm of the object. In trial 1, mice 
were allowed to explore two identical objects for 10 min in the arena and then returned to 
their home cage for 60 min. Mice were then returned to the testing arena for 3 min with one 
object moved to a novel location (trial 2). Care was taken to ensure that the change of 
placement alters both the intrinsic relationship between objects (e.g. a rotation of the moved 
object) and the position relative to internal visual cues (e.g. new location in the arena; one 
wall of testing arena had a pattern). At subsequent time points, new object positions and new 
pairs of objects (from the validated pool of objects) were used to maintain animal interest. In 
addition to using the tracking software to determine the object exploration times, the time 
spent at each object was manually scored by an independent experimenter who was blinded 
to the genotype and treatment. The preference score (%) for OR tasks was calculated as 
([exploration time of the novel object]/[exploration time of both objects]) × 100 from the 
data in trial 2. Automated tracking and manual scoring yielded similar results across groups, 
so we report the automated tracking results.
Y-Maze: The Y-Maze task was used to measure working memory by quantifying 
spontaneous alternation between arms of the maze. The Y-maze consisted of three arms at 
120° and was made of light grey plastic. Each arm was 6-cm wide and 36-cm long, and had 
12.5-cm high walls. The maze was cleaned with 70% ethanol after each mouse. A mouse 
was placed in the Y-maze and allowed to explore for 6 min. Mouse behavior was monitored, 
recorded, and analyzed using the Viewer software. A mouse was considered to have entered 
an arm if the whole body (except for the tail) entered the arm and to have exited if the whole 
body (except for the tail) exited the arm. If an animal consecutively entered three different 
arms, it was counted as an alternating trial. Because the maximum number of triads is the 
total number of arm entries minus 2, the spontaneous alternation score was calculated as 
(number of alternating triads)/(total number of arm entries − 2).
Novel object recognition test: The novel object recognition (NOR) task measures 
recognition memory and is based on rodents’ innate preference for exploring novel objects. 
This test was conducted only in the animals at baseline and after 4 weeks of treatment. The 
testing approach was identical to the OR task, but with a novel object placed at the location 
of one of the initial objects in trial 2. To exclude preference bias for particular objects in the 
first trial one animal would see two of object A and another animal two of object B. In the 
second trial to test for preference for a novel object, both animals see one of object A and 
one of object B. For the repeat of the test at 4 weeks, we used new objects C and D.
ELISA Assay
After the conclusion of the behavior experiments, the APP/PS1 animals that had received α-
Ly6G or isotype control antibodies every 3 days for a month were sacrificed by lethal 
injection of pentobarbital (5 mg/100 g). Brains were quickly extracted and divided along the 
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centerline. One half was immersed in 4% paraformaldehyde in phosphate buffered saline 
(PBS) for later histological analysis and the other half was snap frozen in liquid nitrogen.
The frozen APP/PS1 mouse hemi-brains (Iso-Ctr: n=6, 11.5–12.5 months old; α-Ly6G: n=7, 
11.5–12.5 months old) were weighed and homogenized in 1 ml PBS containing complete 
protease inhibitor (Roche Applied Science) and 1 mM AEBSF (Sigma) using a Dounce 
homogenizer. The homogenates were then sonicated and centrifuged at 14,000 g for 30 min 
at 4° C. The supernatant (PBS-soluble fraction) was removed and stored at −80° C. The 
pellet was re-dissolved in 0.5 ml 70% formic acid, sonicated, and centrifuged at 14,000 g for 
30 min at 4° C, and the supernatant was removed and neutralized using 1M Tris buffer at pH 
11. Protein concentration was measured in the PBS soluble fraction and the formic acid 
soluble fraction using the Pierce BCA Protein Assay (Thermo Fischer Scientific). The PBS 
soluble fraction extracts were diluted 1:5. Formic acid extracts were diluted 1:1 after 
neutralization. These brain extracts were analyzed by sandwich ELISA for Aβ1–40, Aβ1–
42, and Aβ aggregates using commercial ELISA kits and following the manufacturer’s 
protocol (Aβ1–40: KHB3481; Aβ1–42: KHB3441; Aβ aggregates: KHB3491, Thermo 
Fisher Scientific). The Aβ concentration was calculated by comparing the sample 
absorbance with the absorbance of known concentrations of synthetic Aβ1–40 and Aβ1–42 
standards on the same plate. Data was acquired with a Synergy HT plate reader (Biotek) and 
analyzed using Gen5 software (BioTek) and Prism (Graphpad).
Statistical analysis
Boxplots were created using Prism7 (GraphPad). The box extends between the values for the 
25th and 75th percentile of the data. The whiskers extend 1.5 times the difference between 
the value of the 75th and 25th percentile of the data from the top and bottom of the box. 
Values lying outside the whiskers were defined as outliers and the mean was computed 
excluding these outliers. The median is indicated with a black horizontal line inside the box, 
while the mean is indicated with a red horizontal line. Violin plots were created using the 
statistical software package, R51.
Data in all groups was tested for normality using D’Agostino-Pearson omnibus normality 
test. Parametric statistics were used only if the data in all groups in the comparison were 
normally distributed. The statistical significance of differences between multiple groups was 
determined using one-way analysis of variance (ANOVA) followed by Tukey’s multiple 
comparison correction for normally distributed data, and using one-way Kruskal-Wallis 
ANOVA followed by Dunn’s multiple comparison correction for data with a non-normal 
distribution. To compare baseline and post-treatment measurements at multiple time points 
with non-normal data, the Friedman one-way repeated measures non-parametric ANOVA 
followed by Dunn’s multiple comparison correction was used. Statistical comparisons 
between two groups were performed using the Student’s t test or paired t test for normally 
distributed data, or using the Mann-Whitney test or Wilcoxon matched-pairs test for data 
with a non-normal distribution. P-values smaller than 0.05 were considered statistically 
significant. All statistical analysis was performed using Prism7 (GraphPad).
We use a standardized set of significance indicators across all figures in this manuscript. For 
comparisons between groups: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. For matched 
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comparisons before and after treatment: +p<0.05, ++p<0.01. Details of the groups 
compared, animal and capillary numbers, sex distributions, statistical tests, exact p-values, 
and explanatory notes for individual panels are included in the figure captions.
Additional methodological details
Additional information on the methods used in this study are available in the Supplementary 
Methods.
Data availability
The raw data reported in this manuscript are archived at https://doi.org/10.7298/9PR3-D773.
Code availability
Code for 3D tracing, vessel segmentation, analysis of linescan data, and determination of 
amyloid density around capillaries can be obtained by contacting NN or CBS. Code for 
simulation of blood flow in vascular networks can be obtained by contacting SL.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 2PEF imaging of mouse cortical vasculature revealed a higher fraction of plugged 
capillaries in APP/PS1 mice.
(a) Rendering of 2PEF image stack of cortical vasculature (red; Texas Red dextran) and 
amyloid deposits (white; methoxy-X04). (b) Individual brain capillaries were scored as 
flowing or stalled based on the motion of unlabeled blood cells (black) within the 
fluorescently labeled blood plasma (red). (c) Fraction of capillaries with stalled blood flow 
in APP/PS1 and wt mice. (APP/PS1: n = 28 mice (7 female, 21 male), ~22,400 capillaries, 
and wt: n = 12 mice (10 female, 2 male), ~9,600 capillaries; Two-tailed Mann-Whitney, 
p=6.8 X 10−9; Boxplot: whiskers extend 1.5 times the difference between the value of the 
75th and 25th percentile, median=black line and mean= red line.) (d) same data in c shown 
as a function of animal age. Each data point represents the fraction of capillaries stalled in 
one mouse, with a minimum of 800 capillaries scored per mouse. Curves represent sliding 
averages with a 10-week window and shaded areas represent 95% confidence intervals. Data 
from one outlier mouse not shown in c and d: APP/PS1, 42 weeks, 4.4% stalled. (e) Tracing 
of the vascular network in panel a, with stalled capillaries indicated in brown. (f) and (g) 
Histograms showing the topological location of flowing and stalled capillaries in APP/PS1 
mice relative to the nearest penetrating arteriole and ascending venule, respectively (n = 8 
mice (5 female, 3 male), 120 stalled and ~8,700 flowing capillaries).
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Fig. 2. Characterization of the cause, location, and dynamics of capillary occlusions in APP/PS1 
mice.
(a) 2PEF images of stalled capillaries that contained a leukocyte (LEU, left), platelet 
aggregates (PLT) and RBCs (center), or only RBCs (right), distinguished by fluorescent 
labels (red: Texas Red-labeled blood plasma; green: rhodamine 6G-labeled leukocytes and 
platelets; blue: Hoechst-labeled leukocyte nuclei). (b) Fraction of stalled capillaries in 
APP/PS1 mice that contained LEU, one or more RBCs, and PLT, distinguishing cases of 
LEU only, LEU with one or more RBCs, PLT only, PLT with RBCs, and RBCs only (n = 6 
mice (3 female, 3 male) and 106 stalls; error bars represent 95% confidence intervals based 
on binomial statistics.) (c) Projection of 2PEF image stack showing an anti-Ly6G labeled 
cell in a stalled capillary (red: Texas Red-labeled blood plasma; green: anti-Ly6G-Alexa 488 
(0.1 mg/kg animal weight, intravenous). (d) Histogram of the diameter of flowing and 
stalled capillaries in APP/PS1 mice (Averages: 5.8±0.84 µm (stalled), 6.3±1.1 µm (flowing) 
(mean±SD); Two-tailed Mann-Whitney, p=0.000020; n = 7 mice (4 female, 3 male), 116 
stalled and ~8,400 flowing capillaries). (e) Violin plot of the density of amyloid deposits 
within tubes of different radii that followed the capillary centerline for flowing and stalled 
capillary segments in APP/PS1 mice (n = 7 mice (4 female, 3 male), 116 stalled and ~8,400 
flowing capillaries). The vertical range of the violin plot represents the full range of 
measured values, while the width of the violin indicates the frequency of those values. The 
red (black) horizontal line indicates the mean (median) value. (f) Fraction of stalled 
capillaries that remained stalled (red), resumed flowing (green), or resumed flowing and 
then re-stalled (blue) over 15 minutes in APP/PS1 mice (n = 3 mice (all male), 31 capillary 
segments). (g) 2PEF images of the same capillary alternately stalled (arrows) and flowing 
over several weeks (white: methoxy-X04). (h) Probability of an initially stalled capillary to 
be observed stalled again at any subsequent imaging time point, showing both real 
observations in APP/PS1 mice and predictions from a model that assumed each capillary 
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had an equal probability of stalling at each time point (n=4 mice (2 female, 2 male), 49 
stalled capillaries followed from the first imaging session).
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Fig. 3. Administration of antibodies against Ly6G reduced the number of stalled capillaries and 
increased cCBF in APP/PS1 mice.
(a) Number of capillaries with stalled blood flow ~1 hr after α-Ly6G or Iso-Ctr antibody 
administration (4 mg/kg animal weight, intraperitoneal) shown as a fraction of the number of 
stalled capillaries at baseline in APP/PS1 mice (α-Ly6G: n = 6 mice (3 female, 3 male), 
~4,800 capillaries; Iso-Ctr: n = 6 mice (5 female, 1 male), ~4,800 capillaries; two-tailed 
Mann-Whitney, p=0.0004). (b) Projection of 2PEF image stack of brain surface vasculature, 
with surface (red lines) and penetrating (red dots) arterioles identified. For each penetrating 
arteriole, volumetric blood flow is indicated at baseline (left) and after α-Ly6G 
administration (right), along with the percentage of baseline flow. (c) Volumetric blood flow 
in penetrating arterioles measured 60-90 min after α-Ly6G or Iso-Ctr antibody 
administration in young and old APP/PS1 mice and wt control animals shown as a fraction 
of baseline arteriole flow (young APP/PS1 Iso-Ctr: n = 5 mice (1 female, 4 male), 32 
arterioles; old APP/PS1 Iso-Ctr: n = 3 mice (1 female, 2 male), 18 arterioles; young wt α-
Ly6G: n = 5 mice (3 female, 2 male), 30 arterioles; young APP/PS1 α-Ly6G: n = 5 (2 
female, 3 male), 33 arterioles; old APP/PS1 α-Ly6G: n = 3 mice (all male), 22 arterioles; 
one-way Kruskal-Wallis ANOVA with post-hoc using Dunn’s multiple comparison 
correction: young wt α-Ly6G vs. young APP/PS1 α-Ly6G p = 0.0023; young APP/PS1 Iso-
Ctr vs. young APP/PS1 α-Ly6G p = 0.0000012; old APP/PS1 Iso-Ctr vs. old APP/PS1 α-
Ly6G p = 0.00055). (d) CBF map measured using ASL-MRI at baseline and ~5 hr after 
administration of α-Ly6G or Iso-Ctr antibodies in APP/PS1 and wt mice. (e) cCBF 
measurements (ASL-MRI, inset indicates ROI on T2 MRI image) at baseline and ~5 hr after 
administration of α-Ly6G or Iso-Ctr antibodies in APP/PS1 and wt mice (wt α-Ly6G: n = 
10 mice, APP/PS1 α-Ly6G: n = 10 mice, APP/PS1 Iso-Ctr: n = 10 mice; Ordinary one-way 
ANOVA with post hoc using Tukey’s multiple comparison correction to compare across 
groups: baseline wt α-Ly6G vs. baseline APP/PS1 α-Ly6G p=0.011; baseline wt α-Ly6G 
vs. baseline APP/PS1 Iso-Ctr p=0.014; Paired t-test to compare baseline and after treatment 
within a group: baseline APP/PS1 α-Ly6G vs. after APP/PS1 α-Ly6G p=0.0058). All 
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boxplots are defined as: whiskers extend 1.5 times the difference between the value of the 
75th and 25th percentile, median=black line and mean= red line.
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Fig. 4. Administration of α-Ly6G improved short-term memory.
(a) Experimental timeline for behavioral studies. (b) Tracking of mouse nose location from 
video recording during training and trial phases of OR task taken 3-5 hr after administration 
of α-Ly6G or Iso-Ctr antibodies in APP/PS1 mice (representative tracing maps). (c) 
Preference score in OR task and (d) spontaneous alternation in Y-maze task for APP/PS1 
and wt mice at baseline and at 3 hr and 24 hr after a single administration of α-Ly6G or Iso-
Ctr antibodies, and after 4 weeks of treatment every three days. (e) Preference score in NOR 
task for APP/PS1 and wt mice at baseline and after 4 weeks of treatment every three days. 
(APP/PS1 Iso-Ctr: n=10 mice (5 female, 5 female), APP/PS1 α-Ly6G: n=10 mice (5 female, 
5 male), wt α-Ly6G: n=11 mice (7 female, 4 male), wt Iso-Ctr: n=11 mice (8 female, 3 
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male); one-way Kruskal-Wallis ANOVA with post-hoc using Dunn’s multiple comparison 
correction to compare across groups: Object replacement APP/PS1 4wk Iso-Ctr vs. α-Ly6G 
p=0.029; Y-maze APP/PS1 4wk Iso-Ctr vs. α-Ly6G p=0.037; Novel object APP/PS1 4wk 
Iso-Ctr vs. α-Ly6G p=0.038; Friedman one-way repeated measures non-parametric ANOVA 
to compare baseline and after treatment results within a group: Object replacement APP/PS1 
α-Ly6G baseline vs. 3 h p=0.0055, baseline vs. 24h p=0.016, baseline vs. 4wk p=0.045; Y-
maze APP/PS1 α-Ly6G baseline vs. 24h p=0.13, baseline vs 4wk p=0.036; two-tailed 
Wilcoxon matched-pairs signed rank test to compare baseline and post-treatment with novel 
object APP/PS1 α-Ly6G baseline vs 4wk p=0.039.) All boxplots are defined as: whiskers 
extend 1.5 times the difference between the value of the 75th and 25th percentile, 
median=black line and mean= red line. All data in this figure represents the aggregation of 
two independently-conducted sets of behavioral experiments.
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Fig. 5. Administration of α-Ly6G for one month decreased the concentration of Aβ1-40 in 
APP/PS1 mice.
ELISA measurements of (a) Aβ1-40 and (b) Aβ1-42 monomer concentrations after 4 weeks 
of treatment every three days (Iso-Ctr: n=6 mice (4 female, 2 male) and α-Ly6G: n=7 mice 
(4 female, 3 male); two-tailed Mann-Whitney p=0.0023). Boxplots are defined as: whiskers 
extend 1.5 times the difference between the value of the 75th and 25th percentile, 
median=black line and mean= red line.
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Fig. 6. Simulations predicted a similar CBF decrease in mouse and human cortical capillary 
networks with increasing fraction of capillaries with stalled flow.
Spatial maps of simulated blood flow changes caused by stalling of 2% of capillaries 
(indicated by purple spheres) in an mouse cortical vascular network (a, data on the structure 
and connectivity of murine cortical vascular network from 44), and a human network (b, data 
on the structure and connectivity of human cortical vascular network from 22). (c) 
Normalized cortical perfusion as a function of the fraction of capillaries that were occluded, 
expressed as a fraction of the perfusion with no occlusions, in mouse, human, and synthetic 
networks (data points represent the mean and error bars represent the SD across five 
independent simulations).
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